Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in
the leg and lung that can occur with patients hospitalized for acute medical illness, and
compare these results with those of the standard enoxaparin dose and duration regimen. The
safety of rivaroxaban will also be studied.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.